Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus NUTRACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus NUTRACORT.
CAPEX vs NUTRACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Corticosteroid receptor agonist; induces anti-inflammatory proteins and suppresses inflammatory mediators.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
One capsule (200 mg) orally twice daily with meals.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal half-life: 2-4 hours (mean 3 hours). Clinically, dosing every 6-8 hours maintains therapeutic levels.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal (primarily as glucuronide and sulfate conjugates, <10% unchanged) and fecal (biliary excretion of metabolites). Approximately 70-80% renal, 20-30% fecal.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid